Jpmorgan Chase & CO Onconova Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Onconova Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 55 shares of ONTX stock, worth $32. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55
Previous 51
7.84%
Holding current value
$32
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ONTX
# of Institutions
25Shares Held
2.86MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA1.05MShares$616,7030.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA707KShares$417,0830.0% of portfolio
-
Black Rock Inc. New York, NY249KShares$146,8380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA224KShares$132,2100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny218KShares$128,6750.0% of portfolio
About Onconova Therapeutics, Inc.
- Ticker ONTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,895,600
- Market Cap $12.3M
- Description
- Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...